Merck's (MRK) Tredaptive Miss May Benefit Amarin (AMRN) - Analyst

Amarin (Nasdaq: AMRN) shares are pressured today, down about 3.8 percent on the session. But, could there be some good news on the horizon for the pharmceutical company?

Jefferies analyst Thomas Wei thinks so. According to Wei, Merck's (NYSE: MRK) report of Tredaptive missing its primary endpoint of showing cardiovascular benefit in its HPS2-THRIVE strudy might provide incremental benefit for Amarin's Vascepa.

Wei says Merck's failure may mean a shift from niacin therapies -- such as Tredaptive or Abbott's (NYSE: ABT) Niaspan -- over to other therapy classes of cholesterol-lowering medicines like Vascepa.

Merck is down 2.9 percent today.

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $8.53 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies Downgrades ULTA Salon (ULTA) to Hold, 'Competition Intensifying & Prestige Refresh Needed'
• PNC Financial (PNC) PT Lowered to $162 at Jefferies
• Transaction in own shares